-
1.发明申请公开(公告)号：US20240374699A1
公开(公告)日：2024-11-14
申请号：US18531055
申请日：2023-12-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US12128095B2
公开(公告)日：2024-10-29
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G. K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , A61K39/00 , A61P31/04 , A61P37/04 , C08B37/00
CPC classification number: A61K39/0258 , A61P31/04 , A61P37/04 , C08B37/006 , A61K2039/6037 , A61K2039/627
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20230000966A1
公开(公告)日：2023-01-05
申请号：US17772610
申请日：2020-10-28
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Ye Che , Wei Chen , Laurent Oliver Chorro , Ling Chu , Robert G.K. Donald , Matthew Curtis Griffor , Jianxin Gu , Zeqiang Guan , Jin-Hwan Kim , Srinivas Kodali , Scott Ellis Lomberk , Jason Arnold Lotvin , Nishith Merchant , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , David Robert Stead , Karen Kiyoko Takane
IPC: A61K39/108 , C07K14/245
Abstract: In one aspect, the invention relates to a polypeptide derived from E. coli and a fragment thereof, including compositions and methods thereof. Also disclosed herein are compositions that include a polypeptide derived from E. coli and a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. In a further aspect, disclosed herein are mammalian host cells that include sequence(s) encoding a polypeptide derived from E. coli or fragments thereof.
-
4.发明申请公开(公告)号：US20220387613A1
公开(公告)日：2022-12-08
申请号：US17824293
申请日：2022-05-25
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran
Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
-
公开(公告)号：US11260119B2
公开(公告)日：2022-03-01
申请号：US16534457
申请日：2019-08-07
Applicant: Pfizer Inc.
Inventor： Robert G. K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P31/04 , A61P37/04 , A61K39/00
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
Patent Agency Ranking
6.发明授权公开(公告)号：US11090375B2
公开(公告)日：2021-08-17
申请号：US16899738
申请日：2020-06-12
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US10745438B2
公开(公告)日：2020-08-18
申请号：US16505757
申请日：2019-07-09
Applicant: Pfizer Inc.
Inventor： Mingming Han , Rajesh Kumar Kainthan , Jin-Hwan Kim , Avvari Krishna Prasad
IPC: C07K1/107 , C07K14/34 , C07K14/22 , C07K14/315 , A61K39/095 , A61K39/09 , A61K47/64 , C07H3/06 , A61K39/00
Abstract: The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions.
-
8.发明公开公开(公告)号：US20240181028A1
公开(公告)日：2024-06-06
申请号：US18513738
申请日：2023-11-20
Applicant: Pfizer Inc.
Inventor： Catherine Alex , Annaliesa Sybil Anderson , Bishwa Raj Bhetuwal , Zecheng Chen , Kaushik Dutta , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran , Abhishek Ravindra Vartak , YuYing Yang
CPC classification number: A61K39/092 , A61K47/646
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in Prevnar, Synflorix and/or Prevnar 13. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
公开(公告)号：US20230346903A1
公开(公告)日：2023-11-02
申请号：US18060779
申请日：2022-12-01
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
CPC classification number: A61K39/092 , C07K16/1275 , C07K16/44 , A61K39/39 , A61K39/40 , A61K47/10 , A61K47/26 , A61K2039/505
Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
10.发明申请公开(公告)号：US20220387576A1
公开(公告)日：2022-12-08
申请号：US17824295
申请日：2022-05-25
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Caitlyn Gallagher , Jianxin Gu , Isis Kanevsky , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , Naveen Surendran
Abstract: The present invention relates to new conjugated capsular saccharide antigens (glycoconjugates), immunogenic compositions comprising said glycoconjugates and uses thereof.
-
-
-
-
-
-
-
-
-
Search Results
44
records
(took 0.016 seconds)
